glp-1 obesity drug news today oct 23 2025 Use of diabetes and anti-obesity drugs surges nationwide GLP-1 Genetics: How Genes Affect

At 2.4 mg weekly, average weight loss reached about 15% over 68 weeks. Response varied widely: 86% lost at least 5%, 69% lost 10%, half lost 15%, and about one-third lost 20%. These results describe that cohort rather than a universal forecast

Insurers weigh the short-term cost of GLP-1 therapies (up to ~$17K annually) against the long-term savings from reduced obesity-related complications

to accelerate the regeneration of the nasal cavity mucosa after surgical interventions

As of July 2324, 2026, an FDA advisory committee meeting was scheduled to discuss BPC-157-, KPV-, and TB-500-related bulk substances nominated for possible use in compounding